NASDAQ : CBUS
Cibus, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.35 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 103.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 95.54M |
| Enterprise Value | 361.37M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 76.43M |
| Shares Outstanding | 76.43M |
| Shares Change (YoY) | +95.73% |
| Shares Change (QoQ) | +17.72% |
| Owned by Insiders (%) | 25.07% |
| Owned by Institutions (%) | 29.68% |
| Float | 57.24M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.94 |
| Forward PS | 11.05 |
| PB Ratio | 6.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 84.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.62 |
| Quick Ratio | 1.49 |
| Debt / Equity | 19.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.46 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -223.16% |
| Return on Assets (ROA) | -10.22% |
| Return on Invested Capital (ROIC) | -10.75% |
| Return on Capital Employed (ROCE) | -18.04% |
| Weighted Average Cost of Capital (WACC) | 10.91% |
| Revenue Per Employee | $36,839 |
| Profits Per Employee | -$832,153 |
| Employee Count | 118 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 13,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.57 |
| 52-Week Price Change | -18.87% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 35.35 |
| Average Volume (20 Days) | 78,246 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.13M |
| Short Previous Month | 3.32M |
| Short % of Shares Out | 4.09% |
| Short % of Float | 5.46% |
| Short Ratio (days to cover) | 23.75 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.35M |
| Gross Profit | 4.35M |
| Operating Income | -53.94M |
| Pretax Income | -99.61M |
| Net Income | -98.19M |
| EBITDA | -48.87M |
| EBIT | -53.94M |
| Loss Per Share | -$1.58 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 20.43M |
| Total Debt | 286.26M |
| Net Cash | -265.83M |
| Net Cash Per Share | -$3.48 |
| Equity (Book Value) | 14.80M |
| Book Value Per Share | 0.19 |
| Working Capital | 9.01M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -46.05M |
| Capital Expenditures | -267,000 |
| Depreciation & Amortization | 5.07M |
| Net Borrowing | -1.18M |
| Free Cash Flow | -46.32M |
| FCF Per Share | -$0.61 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -1,240.90% |
| Pretax Margin | -2,291.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -95.73% |
| Shareholder Yield | -95.73% |
| Earnings Yield | -126.53% |
| FCF Yield | -46.44% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.33 |
| Price Target Difference | 1,046.40% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 135.53% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 1, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.33 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |